This is consistent with the cohort described by Elez et al. [16], which demonstrated improved progression-free survival on combined BRAF and EGFR inhibition therapy in patients with RNF43-mutated tumours compared to those with wild-type tumours. The gene discussed is RNF43; the disease is neoplasm.